Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

STOK – Stoke Therapeutics, Inc.

Float Short %

24.9

Margin Of Safety %

-42

Put/Call OI Ratio

0.31

EPS Next Q Diff

-0.24

EPS Last/This Y

1.91

EPS This/Next Y

-3.18

Price

19.55

Target Price

24.22

Analyst Recom

1.18

Performance Q

105.89

Relative Volume

1.59

Beta

1.08

Ticker: STOK




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25STOK13.10.150.178159
2025-07-28STOK12.820.150.058389
2025-07-29STOK12.510.150.188415
2025-07-30STOK12.870.140.118616
2025-07-31STOK12.850.140.028662
2025-08-01STOK12.920.140.058652
2025-08-04STOK13.130.140.018644
2025-08-05STOK12.950.140.448662
2025-08-06STOK13.160.140.018665
2025-08-07STOK13.260.110.0111172
2025-08-08STOK13.10.110.1711461
2025-08-11STOK13.140.110.1511593
2025-08-12STOK13.550.110.5611633
2025-08-13STOK16.910.140.2912417
2025-08-14STOK17.170.280.1111920
2025-08-15STOK18.220.300.2311496
2025-08-18STOK18.530.240.379333
2025-08-19STOK18.490.250.799354
2025-08-20STOK19.330.272.649534
2025-08-21STOK19.670.310.149840
2025-08-22STOK19.570.310.0710009
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25STOK13.10-7.0- -0.05
2025-07-28STOK12.74-8.8- 0.12
2025-07-29STOK12.50-16.8- 0.12
2025-07-30STOK12.87-16.8- 0.12
2025-07-31STOK12.85-16.8- 0.12
2025-08-01STOK12.91-16.8- 0.12
2025-08-04STOK13.14-16.8- 0.12
2025-08-05STOK12.96-16.8- 0.12
2025-08-06STOK13.16-16.8- 0.12
2025-08-07STOK13.25-16.8- 0.12
2025-08-08STOK13.10-16.8- 0.12
2025-08-11STOK13.15-16.8- 0.12
2025-08-12STOK13.54-16.8- 0.12
2025-08-13STOK16.91-16.8- 0.12
2025-08-14STOK17.15-16.8- 0.12
2025-08-15STOK18.19-16.8- 0.35
2025-08-18STOK18.52-16.8- 0.35
2025-08-19STOK18.49-25.5- 0.26
2025-08-20STOK19.31-25.5- 0.26
2025-08-21STOK19.67-25.5- 0.26
2025-08-22STOK19.55-25.5- 0.26
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25STOK-25.980.0725.07
2025-07-28STOK-25.98-0.7325.07
2025-07-29STOK-25.98-0.7325.07
2025-07-30STOK-25.98-0.7325.07
2025-07-31STOK-25.98-0.7325.07
2025-08-01STOK-25.98-0.7325.07
2025-08-04STOK-25.98-1.3325.07
2025-08-05STOK-26.01-1.3325.07
2025-08-06STOK-26.01-1.3325.07
2025-08-07STOK-26.01-1.3325.07
2025-08-08STOK-26.01-1.3325.07
2025-08-11STOK-26.01-1.3625.07
2025-08-12STOK-26.02-1.3624.93
2025-08-13STOK-26.02-1.3624.93
2025-08-14STOK-26.02-1.3624.93
2025-08-15STOK-25.95-1.3624.83
2025-08-18STOK-26.042.4124.89
2025-08-19STOK-25.832.4124.89
2025-08-20STOK-25.942.4124.89
2025-08-21STOK-25.942.4124.89
2025-08-22STOK-25.942.4124.90
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.4

Avg. EPS Est. Current Quarter

-0.59

Avg. EPS Est. Next Quarter

-0.64

Insider Transactions

-25.94

Institutional Transactions

2.41

Beta

1.08

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

5

Fair Value

11.29

Quality Score

68

Growth Score

29

Sentiment Score

89

Actual DrawDown %

72.7

Max Drawdown 5-Year %

-95.2

Target Price

24.22

P/E

23.15

Forward P/E

PEG

P/S

5.36

P/B

3.2

P/Free Cash Flow

17.53

EPS

0.84

Average EPS Est. Cur. Y​

0.26

EPS Next Y. (Est.)

-2.92

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

26.26

Relative Volume

1.59

Return on Equity vs Sector %

-9

Return on Equity vs Industry %

3.9

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.18

EBIT Estimation

Stoke Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 128
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today
news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance
stock history STOK – Stoke Therapeutics, Inc. invest stock market
stock prices STOK premarket after hours
ticker STOK fair value insiders trading